Absci Corp (ABSI)vsModerna Inc (MRNA)
ABSI
Absci Corp
$7.51
-7.97%
HEALTHCARE · Cap: $1.74B
MRNA
Moderna Inc
$195.00
-2.17%
HEALTHCARE · Cap: $101.49B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 161655% more annual revenue ($2.52B vs $1.56M). ABSI leads profitability with a 0.0% profit margin vs -110.5%. MRNA earns a higher WallStSmart Score of 31/100 (F).
ABSI
Avoid20
out of 100
Grade: F
MRNA
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-65.6%
Fair Value
$1.57
Current Price
$7.51
$5.94 premium
Margin of Safety
+73.2%
Fair Value
$150.95
Current Price
$195.00
$44.05 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Large-cap with strong market position
Revenue surging 29.2% year-over-year
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Trading at 11.5x book value
Weak financial health signals
ROE of -40.8% — below average capital efficiency
Earnings declined 85.1%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABSI
The strongest argument for ABSI centers on Debt/Equity.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Revenue Growth. Revenue growth of 29.2% demonstrates continued momentum.
Bear Case : ABSI
The primary concerns for ABSI are EPS Growth, Market Cap, Profit Margin.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
ABSI profiles as a value stock while MRNA is a growth play — different risk/reward profiles.
ABSI carries more volatility with a beta of 2.19 — expect wider price swings.
MRNA is growing revenue faster at 29.2% — sustainability is the question.
ABSI generates stronger free cash flow (-29M), providing more financial flexibility.
Bottom Line
MRNA scores higher overall (31/100 vs 20/100) and 29.2% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Absci Corp
HEALTHCARE · BIOTECHNOLOGY · USA
Absci Corp (ABSI) is a cutting-edge biotechnology company that utilizes a proprietary AI-driven platform to revolutionize drug discovery and development. By facilitating the rapid generation of high-quality proteins and therapeutic candidates, Absci effectively shortens development timelines and lowers associated costs, establishing itself as a key innovator within the biopharmaceutical sector. The company's robust pipeline, complemented by strategic partnerships, underscores its commitment to advancing next-generation therapies that address critical medical needs and improve patient outcomes.
Visit Website →Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?